Core Insights - KalVista Pharmaceuticals reported early commercial momentum for its hereditary angioedema treatment EKTERLY, with increasing prescriber adoption and repeat prescriptions following its mid-2025 launch [1] Group 1: Product Launch and Market Performance - EKTERLY received FDA approval in July 2025 as the first and only oral on-demand treatment for acute attacks of hereditary angioedema in patients aged 12 and older [2] - The company disclosed preliminary net product revenue of approximately $35 million for Q4 and $49 million for fiscal year 2025, following the commercial launch in July 2025 [3] - Prescription refills have overtaken new prescriptions as the primary revenue driver, indicating growing continuity of use among patients [4] Group 2: Expansion and Future Plans - KalVista has granted Multicare Pharmaceuticals exclusive rights to commercialize sebetralstat in Latin America, overseeing regulatory approvals and distribution in Brazil, Argentina, Colombia, and Mexico [4][5] - The company completed enrollment in the Phase 3 KONFIDENT-KID trial for children aged 2 to 11 with hereditary angioedema, finishing a year ahead of schedule, with plans to submit a new drug application in Q3 2026 [5] Group 3: Stock Performance - KalVista Pharmaceuticals stock increased by 13.18%, reaching $17.86 at the time of publication [6]

KalVista Pharmaceuticals Corporate Overview January 2026 1 Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be ...